QT Imaging Holdings Inc. reported first-half revenue of $14.0 million for 2026, a 116% increase from the same period a year earlier, as scanner shipments doubled and international markets expanded. The company, which develops breast imaging technology, raised its full-year revenue guidance to approximately $39 million, up from prior expectations.
The company shipped 28 Breast Acoustic CT scanners in the first six months of 2026, compared with 14 in the first half of 2025. More than 12,000 women have been imaged using QT Imaging’s technology to date, the company said. Revenue for 2025 totaled $18.9 million, up from $4.9 million in 2024, while 2023 revenue was zero.
QT Imaging completed a $10 million underwritten public offering in the second quarter, boosting its cash and restricted cash position to approximately $14.2 million as of August 7. The company also extended the maturity of its senior secured term loan to March 31, 2029.
Regulatory progress included two FDA clearances in early 2026 for enhanced scanner configurations and software functionality. The company passed its first routine FDA inspection in July with no Form 483 observations. Internationally, QT Imaging secured authorizations in Saudi Arabia, the United Arab Emirates, and Israel.
The American Medical Association approved a Category III CPT code for 3D quantitative transmission volumetric ultrasound tomography of the breast, effective January 1, 2027. The company is relocating its headquarters and manufacturing operations to a 22,000-square-foot facility in Petaluma, California, which will reduce lease costs per square foot by about 55% while expanding operational space by more than 2.5 times.
